Callum G Fraser

List of Publications by Citations

136 papers	3,910 citations	31 h-index	57 g-index
158 ext. papers	4,499 ext. citations	4.4 avg, IF	5.86 L-index

#	Paper	IF	Citations
136	Proposals for setting generally applicable quality goals solely based on biology. *Annals of Clinical Biochemistry*, **1997**, 34 (Pt 1), 8-12	2.2	285
135	Defining analytical performance specifications: Consensus Statement from the 1st Strategic Conference of the European Federation of Clinical Chemistry and Laboratory Medicine. *Clinical Chemistry and Laboratory Medicine*, **2015**, 53, 833-5	5.9	274
134	Analytical Performance Characteristics Should Be Judged against Objective Quality Specifications. *Clinical Chemistry*, **1999**, 45, 321-323	5.5	158
133	Reference change values. *Clinical Chemistry and Laboratory Medicine*, **2011**, 50, 807-12	5.9	134
132	Inherent biological variation and reference values. *Clinical Chemistry and Laboratory Medicine*, **2004**, 42, 758-64	5.9	127
131	Advances in Fecal Occult Blood Tests: the FIT revolution. *Digestive Diseases and Sciences*, **2015**, 60, 609-22	2.4	125
130	A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. *Journal of the National Cancer Institute*, **2012**, 104, 810-4	9.7	123
129	Faecal haemoglobin and faecal calprotectin as indicators of bowel disease in patients presenting to primary care with bowel symptoms. *Gut*, **2016**, 65, 1463-9	19.2	116
128	Population screening for colorectal cancer means getting FIT: the past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT). *Gut and Liver* , **2014**, 8, 117-30	4.8	112
127	Does renal dysfunction predict mortality after acute stroke? A 7-year follow-up study. *Stroke*, **2002**, 33, 1630-5	6.7	100
126	Faecal immunochemical tests (FIT) can help to rule out colorectal cancer in patients presenting in primary care with lower abdominal symptoms: a systematic review conducted to inform new NICE DG30 diagnostic guidance. *BMC Medicine*, **2017**, 15, 189	11.4	68
125	Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. *International Journal of Cancer*, **2011**, 128, 3-11	7.5	68
124	Biological variation database: structure and criteria used for generation and update. *Clinical Chemistry and Laboratory Medicine*, **2015**, 53, 299-305	5.9	65
123	Faecal haemoglobin concentration is related to severity of colorectal neoplasia. *Journal of Clinical Pathology*, **2013**, 66, 415-9	3.9	64
122	Biologic variation of common hematologic laboratory quantities in the elderly. *American Journal of Clinical Pathology*, **1989**, 92, 465-70	1.9	64
121	Faecal haemoglobin concentrations by gender and age: implications for population-based screening for colorectal cancer. *Clinical Chemistry and Laboratory Medicine*, **2011**, 50, 935-40	5.9	62
120	Clinical outcomes using a faecal immunochemical test for haemoglobin as a first-line test in a national programme constrained by colonoscopy capacity. *United European Gastroenterology Journal*, **2013**, 1, 198-205	5.3	57

119	Low faecal haemoglobin concentration potentially rules out significant colorectal disease. *Colorectal Disease*, **2013**, 15, e151-9	2.1	57
118	Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study. *Lancet Oncology, The*, **2006**, 7, 127-31	21.7	57
117	Impact of introducing a faecal immunochemical test (FIT) for haemoglobin into primary care on the outcome of patients with new bowel symptoms: a prospective cohort study. *BMJ Open Gastroenterology*, **2019**, 6, e000293	3.9	53
116	Pre-notification increases uptake of colorectal cancer screening in all demographic groups: a randomized controlled trial. *Journal of Medical Screening*, **2011**, 18, 24-9	1.4	49
115	Use of a faecal immunochemical test for haemoglobin can aid in the investigation of patients with lower abdominal symptoms. *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, 595-602	5.9	48
114	Test result variation and the quality of evidence-based clinical guidelines. *Clinica Chimica Acta*, **2004**, 346, 19-24	6.2	47
113	The fecal hemoglobin concentration, age and sex test score: Development and external validation of a simple prediction tool for colorectal cancer detection in symptomatic patients. *International Journal of Cancer*, **2017**, 140, 2201-2211	7.5	44
112	Faecal haemoglobin concentrations vary with sex and age, but data are not transferable across geography for colorectal cancer screening. *Clinical Chemistry and Laboratory Medicine*, **2014**, 52, 1211-6	5.9	44
111	Reference change values: the way forward in monitoring. *Annals of Clinical Biochemistry*, **2009**, 46, 264-5	2.2	44
110	Combination of analytical quality specifications based on biological within- and between-subject variation. *Annals of Clinical Biochemistry*, **2002**, 39, 543-50	2.2	43
109	Impact of the UK colorectal cancer screening pilot studies on incidence, stage distribution and mortality trends. *Cancer Epidemiology*, **2012**, 36, e232-42	2.8	41
108	Use of a faecal immunochemical test narrows current gaps in uptake for sex, age and deprivation in a bowel cancer screening programme. *Journal of Medical Screening*, **2013**, 20, 80-5	1.4	39
107	Detection capability of quantitative faecal immunochemical tests for haemoglobin (FIT) and reporting of low faecal haemoglobin concentrations. *Clinical Chemistry and Laboratory Medicine*, **2019**, 57, 611-616	5.9	32
106	Reference change values for monitoring dehydration. *Clinical Chemistry and Laboratory Medicine*, **2011**, 49, 1033-7	5.9	31
105	The influence of analytical bias on diagnostic misclassifications. *Clinica Chimica Acta*, **1997**, 260, 189-206	6.2	31
104	Effect of delay in sampling on haemoglobin determined by faecal immunochemical tests. *Annals of Clinical Biochemistry*, **2008**, 45, 604-5	2.2	31
103	Experience with a two-tier reflex gFOBT/FIT strategy in a national bowel screening programme. *Journal of Medical Screening*, **2012**, 19, 8-13	1.4	30
102	Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited. *Journal of Medical Screening*, **2016**, 23, 130-4	1.4	29

101	Biologic variation of urinary albumin: consequences for analysis, specimen collection, interpretation of results, and screening programs. *American Journal of Kidney Diseases*, **1989**, 13, 35-7	7.4	29
100	Terms and symbols used in studies on biological variation: the need for harmonization. *Clinical Chemistry*, **2015**, 61, 438-9	5.5	28
99	Population-based colorectal cancer screening programmes using a faecal immunochemical test: should faecal haemoglobin cut-offs differ by age and sex?. *BMC Cancer*, **2017**, 17, 577	4.8	28
98	Nonadherence with angiotensin-converting enzyme inhibitor therapy: a comparison of different ways of measuring it in patients with chronic heart failure. *Journal of the American College of Cardiology*, **1999**, 34, 2072-7	15.1	27
97	Impact of faecal haemoglobin concentration on colorectal cancer mortality and all-cause death. *BMJ Open*, **2013**, 3, e003740	3	26
96	Objective criteria for partitioning Gaussian-distributed reference values into subgroups. *Clinical Chemistry*, **2002**, 48, 338-52	5.5	26
95	Clinical utility of one versus two faecal immunochemical test samples in the detection of advanced colorectal neoplasia in symptomatic patients. *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, 125-32	3.9	25
94	Application of NICE guideline NG12 to the initial assessment of patients with lower gastrointestinal symptoms: not FIT for purpose?. *Annals of Clinical Biochemistry*, **2018**, 55, 69-76	2.2	24
93	Occult blood in faeces is associated with all-cause and non-colorectal cancer mortality. *Gut*, **2018**, 67, 2116-2123	19.2	24
92	A standard for Faecal Immunochemical TesTs for haemoglobin evaluation reporting (FITTER). *Annals of Clinical Biochemistry*, **2014**, 51, 301-2	2.2	24
91	Acute effects of captopril on the renal actions of furosemide in patients with chronic heart failure. *American Heart Journal*, **1993**, 126, 879-86	4.9	24
90	Deprivation and faecal haemoglobin: implications for bowel cancer screening. *Journal of Medical Screening*, **2014**, 21, 95-7	1.4	23
89	Calculation of limits for significant bidirectional changes in two or more serial results of a biomarker based on a computer simulation model. *Annals of Clinical Biochemistry*, **2015**, 52, 434-40	2.2	22
88	Faecal occult blood tests--eliminate, enhance or update?. *Annals of Clinical Biochemistry*, **2008**, 45, 117-21	2.2	22
87	Optimal analytical performance for point of care testing. *Clinica Chimica Acta*, **2001**, 307, 37-43	6.2	22
86	The 1999 Stockholm Consensus Conference on quality specifications in laboratory medicine. *Clinical Chemistry and Laboratory Medicine*, **2015**, 53, 837-40	5.9	21
85	Faecal immunochemical tests (FIT) in the assessment of patients presenting with lower bowel symptoms: Concepts and challenges. *Journal of the Royal College of Surgeons of Edinburgh*, **2018**, 16, 302-308	2.5	21
84	Calculation of limits for significant unidirectional changes in two or more serial results of a biomarker based on a computer simulation model. *Annals of Clinical Biochemistry*, **2015**, 52, 237-44	2.2	20

83	Desirable standards for hematology tests: a proposal. *American Journal of Clinical Pathology*, **1987**, 88, 667-9	1.9	20
82	Setting up a service for a faecal immunochemical test for haemoglobin (FIT): a review of considerations, challenges and constraints. *Journal of Clinical Pathology*, **2018**, 71, 1041-1045	3.9	20
81	A comparative effectiveness trial of two faecal immunochemical tests for haemoglobin (FIT). Assessment of test performance and adherence in a single round of a population-based screening programme for colorectal cancer. *Gut*, **2018**, 67, 485-496	19.2	19
80	Guaiac based faecal occult blood testing for colorectal cancer screening: an obsolete strategy?. *Gut*, **2012**, 61, 959-60	19.2	19
79	Strategies to set global analytical quality specifications in laboratory medicine: 10 years on from the Stockholm consensus conference. *Accreditation and Quality Assurance*, **2010**, 15, 323-330	0.7	19
78	Evaluation of a card collection-based faecal immunochemical test in screening for colorectal cancer using a two-tier reflex approach. *Gut*, **2007**, 56, 1415-8	19.2	19
77	Uptake trends in the Scottish Bowel Screening Programme and the influences of age, sex, and deprivation. *Journal of Medical Screening*, **2018**, 25, 24-31	1.4	17
76	Automated immunochemical quantitation of haemoglobin in faeces collected on cards for screening for colorectal cancer. *Gut*, **2008**, 57, 1256-60	19.2	17
75	Transition to quantitative faecal immunochemical testing from guaiac faecal occult blood testing in a fully rolled-out population-based national bowel screening programme. *Gut*, **2021**, 70, 106-113	19.2	17
74	A future for faecal haemoglobin measurements in the medical laboratory. *Annals of Clinical Biochemistry*, **2012**, 49, 518-26	2.2	16
73	Polymorphisms of the angiotensin converting enzyme gene in early-onset and late-onset pre-eclampsia. *Journal of Maternal-Fetal and Neonatal Medicine*, **2010**, 23, 874-9	2	16
72	Components of variance of some plasma constituents in patients with myocardial infarction. *Annals of Clinical Biochemistry*, **1982**, 19, 431-4	2.2	16
71	Faecal immunochemical tests for haemoglobin (FIT) in the assessment of patients with lower abdominal symptoms: current controversies. *Gastroenterología Y Hepatología*, **2019**, 42, 263-270	0.9	15
70	Interval cancers in a national colorectal cancer screening programme. *United European Gastroenterology Journal*, **2016**, 4, 587-94	5.3	12
69	Nonadherence with ACE inhibitors is common and can be detected in clinical practice by routine serum ACE activity. *Congestive Heart Failure*, **2001**, 7, 43-46		12
68	Faecal haemoglobin concentration is related to detection of advanced colorectal neoplasia in the next screening round. *Journal of Medical Screening*, **2017**, 24, 62-68	1.4	11
67	How to improve the performances of Fecal Immunological Tests (FIT): Need for standardization of the sampling and pre-analytical phases and revision of the procedures for comparison of methods. *International Journal of Biological Markers*, **2015**, 30, e127-31	2.8	11
66	Reference change values may need some improvement but are invaluable tools in laboratory medicine. *Clinical Chemistry and Laboratory Medicine*, **2012**, 50,	5.9	11

65	Assay validation and biological variation of serum receptor for advanced glycation end-products. *Annals of Clinical Biochemistry*, **2008**, 45, 518-9	2.2	11
64	Age-related changes in laboratory test results. Clinical implications. *Drugs and Aging*, **1993**, 3, 246-57	4.7	11
63	Faecal haemoglobin distributions by sex, age, deprivation and geographical region: consequences for colorectal cancer screening strategies. *Clinical Chemistry and Laboratory Medicine*, **2020**, 58, 2073-2080	5.9	11
62	Appraisal of the faecal haemoglobin, age and sex test (FAST) score in assessment of patients with lower bowel symptoms: an observational study. *BMC Gastroenterology*, **2019**, 19, 213	3	11
61	Yield of colorectal cancer at colonoscopy according to faecal haemoglobin concentration in symptomatic patients referred from primary care. *Colorectal Disease*, **2021**, 23, 1615-1621	2.1	10
60	Do other variables add value to assessment of the risk of colorectal disease using faecal immunochemical tests for haemoglobin?. *Annals of Clinical Biochemistry*, **2019**, 56, 472-479	2.2	9
59	Measurement of faecal haemoglobin with a faecal immunochemical test can assist in defining which patients attending primary care with rectal bleeding require urgent referral. *Annals of Clinical Biochemistry*, **2020**, 57, 325-327	2.2	9
58	Impact of preanalytical factors on fecal immunochemical tests: need for new strategies in comparison of methods. *International Journal of Biological Markers*, **2015**, 30, e269-74	2.8	9
57	Do new concepts for deriving permissible limits for analytical imprecision and bias have any advantages over existing consensus?. *Clinical Chemistry and Laboratory Medicine*, **2011**, 49, 637-40	5.9	9
56	The authorÃ¢ reply. Analytic goals are targets, not inflexible criteria of acceptability. *American Journal of Clinical Pathology*, **1988**, 89, 703-5	1.9	9
55	Screening for colorectal neoplasia with faecal tests. *Lancet Oncology, The*, **2011**, 12, 516-7	21.7	8
54	Quality specifications for imprecision of B-type natriuretic peptide assays. *Clinical Chemistry*, **2005**, 51, 1307-9	5.5	8
53	Analytical Performance Specifications for 25-Hydroxyvitamin D Examinations. *Nutrients*, **2021**, 13,	6.7	8
52	Different percentages of false-positive results obtained using five methods for the calculation of reference change values based on simulated normal and ln-normal distributions of data. *Annals of Clinical Biochemistry*, **2016**, 53, 692-698	2.2	7
51	Faecal haemoglobin concentrations do vary across geography as well as with age and sex: ramifications for colorectal cancer screening. *Clinical Chemistry and Laboratory Medicine*, **2015**, 53, e235-7	5.9	7
50	Confirmation of analytical performance characteristics required for the reference change value applied in patient monitoring. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2015**, 75, 628-30	2	7
49	Faecal haemoglobin can define risk of colorectal neoplasia at surveillance colonoscopy in patients at increased risk of colorectal cancer. *United European Gastroenterology Journal*, **2020**, 8, 559-566	5.3	7
48	Faecal haemoglobin concentration thresholds for reassurance and urgent investigation for colorectal cancer based on a faecal immunochemical test in symptomatic patients in primary care. *Annals of Clinical Biochemistry*, **2021**, 58, 211-219	2.2	7

47	Quality specifications for haemoglobin A1c assays in the monitoring of diabetes. *Upsala Journal of Medical Sciences*, **1993**, 98, 335-8	2.8	6
46	Comparison of quantitative faecal immunochemical tests for haemoglobin (FIT) for asymptomatic population screening. *Translational Cancer Research*, **2016**, 5, S916-S919	0.3	6
45	Acceptance quality checks for qualitative fecal immunochemical tests ensure screening program consistency. *International Journal of Cancer*, **2011**, 128, 247-8; author reply 248-9	7.5	5
44	Use of Appropriate Analytic Goals. *American Journal of Clinical Pathology*, **1983**, 79, 759-760	1.9	5
43	Goals for clinical biochemistry analytical imprecision: a graphic approach. *Pathology*, **1980**, 12, 209-18	1.6	5
42	Interpretation of faecal haemoglobin concentration data in colorectal cancer screening and in assessment of symptomatic patients. *Journal of Laboratory and Precision Medicine*,2, 96-96	1.1	5
41	Faecal Immunochemical Tests (FIT) for Haemoglobin for Timely Assessment of Patients with Symptoms of Colorectal Disease **2018**, 39-66		5
40	Calculation of reference change values using more than two results is a difficult task. *Annals of Clinical Biochemistry*, **2017**, 54, 412-413	2.2	4
39	Can the performance of a quantitative FIT-based colorectal cancer screening programme be enhanced by lowering the threshold and increasing the interval?. *Gut*, **2018**, 67, 993-994	19.2	4
38	Assessment of faecal haemoglobin concentration distributions is vital for faecal immunochemical test (FIT)-based colorectal cancer screening programmes. *Journal of Medical Screening*, **2016**, 23, 52-3	1.4	4
37	The clinical view of turnaround times for stat tests. *American Journal of Clinical Pathology*, **1979**, 72, 885	1.9	4
36	RE: A Proposal to Standardize Reporting Units for Fecal Immunochemical Tests for Hemoglobin. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	3
35	Faecal Haemoglobin Estimated by Faecal Immunochemical Tests-An Indicator of Systemic Inflammation with Real Clinical Potential. *Diagnostics*, **2021**, 11,	3.8	3
34	Faecal haemoglobin concentration and personalised assessment of the risk of colorectal neoplasia. *Journal of Laboratory and Precision Medicine*,2, 71-71	1.1	3
33	Changes in prevalence of faecal occult blood positivity over time. *Journal of Medical Screening*, **2019**, 26, 191-196	1.4	2
32	Biological variation: a rapidly evolving aspect of laboratory medicine. *Journal of Laboratory and Precision Medicine*, **2017**, 2, 35-35	1.1	2
31	Valid analytical performance specifications for combined analytical bias and imprecision for the use of common reference intervals. *Annals of Clinical Biochemistry*, **2018**, 55, 612-615	2.2	2
30	Analytical performance specifications for changes in assay bias (Bias) for data with logarithmic distributions as assessed by effects on reference change values. *Annals of Clinical Biochemistry*, **2016**, 53, 686-691	2.2	2

29	Predicting mortality using two renal function estimation methods in hospitalised stroke patients. *International Journal of Cardiology*, **2010**, 139, 307-9	3.2	2
28	Polymorphisms of the angiotensin converting enzyme gene in relation to intrauterine growth restriction. *Acta Obstetricia Et Gynecologica Scandinavica*, **2010**, 89, 1197-201	3.8	2
27	Quality specifications in laboratory medicine □current consensus views. *Accreditation and Quality Assurance*, **1999**, 4, 410-413	0.7	2
26	Clinically useful limits (CUL) criteria best based on within-subject biologic variation. *American Journal of Clinical Pathology*, **1989**, 92, 256-7	1.9	2
25	A novel approach to the assessment of drug compliance in the elderly. *Gerontology*, **1991**, 37, 339-44	5.5	2
24	The Author Replies as Follow: Attainment of Pre-Analytical Goals is Vital. *Annals of Clinical Biochemistry*, **1987**, 24, 116-116	2.2	2
23	The Effect of the Variability in Fecal Immunochemical Test Sample Collection Technique on Clinical Performance. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 175-181	4	2
22	Association between faecal occult bleeding and medicines prescribed for chronic disease: a data linkage study. *Journal of Clinical Pathology*, **2021**, 74, 664-667	3.9	2
21	Urinalysis in an Australian teaching hospital. *Medical Journal of Australia*, **1982**, 1, 300-1	4	2
20	Variation in changes in the incidence of colorectal cancer by age and association with screening uptake: an observational study. *BMJ Open*, **2020**, 10, e037925	3	2
19	Faecal immunochemical tests for haemoglobin (FIT) in the assessment of patients with lower abdominal symptoms: current controversies. *Gastroenterología Y Hepatología (English Edition)*, **2019**, 42, 263-270	0.1	1
18	A dynamic reference change value model applied to ongoing assessment of the steady state of a biomarker using more than two serial results. *Annals of Clinical Biochemistry*, **2019**, 56, 283-294	2.2	1
17	Problems with the investigation of a problem with faecal occult blood tests. *Annals of Clinical Biochemistry*, **2010**, 47, 391-2; author reply 392	2.2	1
16	Biological variation: a still maturing aspect of laboratory medicine. *Advances in Laboratory Medicine / Avances En Medicina De Laboratorio*, **2020**, 1,	1.3	1
15	Assuring the quality of examinations using faecal immunochemical tests for haemoglobin (FIT). *Clinical Chemistry and Laboratory Medicine*, **2020**, 59, 245-247	5.9	1
14	Faecal haemoglobin concentrations in women and men diagnosed with colorectal cancer in a national screening programme. *Journal of Medical Screening*, **2021**, 9691413211056970	1.4	1
13	Quality Indicators and Benchmarks for Guideline-Recommended Fecal Occult Blood Tests **2015**, 65-79		1
12	Randomized controlled trial: Flexible sigmoidoscopy as an adjunct to faecal occult blood testing in population screening. *Journal of Medical Screening*, **2020**, 27, 59-67	1.4	1

List of Publications

11	The importance of comparing quantitative faecal immunochemical tests (FIT) before selecting one for a population-based colorectal cancer screening programme. *Journal of Laboratory and Precision Medicine*, **2018**, 3, 7-7	1.1	1
10	Replicate and Repeat FIT in Symptomatic Patients: A Systematic Review.. *Annals of Clinical Biochemistry*, **2022**, 45632221096036	2.2	1
9	Low Sensitivity of Fecal Immunochemical Tests (FIT) for Detection of Sessile Serrated Adenomas/Polyps Confirmed Over Clinical Setting, Geography, and FIT System. *Digestive Diseases and Sciences*, **2019**, 64, 3024-3026	4	0
8	Faecal haemoglobin concentration in adenoma, before and after polypectomy, approaches the ideal tumour marker.. *Annals of Clinical Biochemistry*, **2022**, 45632221080897	2.2	0
7	AuthorsR reply to the letter to Editor (Annals of Clinical Biochemistry): RA simple approach to derive Z-score of reference change value involving more than two serial resultsR. *Annals of Clinical Biochemistry*, **2015**, 52, 718-9	2.2	
6	Experience with a wipe guaiac-based faecal occult blood test as an alternative test in a bowel screening programme. *Journal of Medical Screening*, **2010**, 17, 211-3	1.4	
5	Grossly elevated serum angiotensin-converting enzyme activities are still suppressible with ACE inhibitor therapy. *JRAAS - Journal of the Renin-Angiotensin-Aldosterone System*, **2002**, 3, 138	3	
4	Dr Per Hyltoft Petersen: an appreciation. *Clinical Chemistry and Laboratory Medicine*, **2022**, 60, 299-300	5.9	
3	Use of fecal immunochemical testing in patients presenting in primary care with lower GI symptoms. *Cmaj*, **2020**, 192, E377	3.5	
2	Optimal Analytical Performance for POCT. *Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine*, **2001**, 13, 3-8	2.4	
1	One or two faecal immunochemical tests in an organised population-based colorectal cancer screening programme in Murcia (Spain).. *Journal of Medical Screening*, **2022**, 9691413221094919	1.4	